Loading clinical trials...
Loading clinical trials...
An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee
Conditions
Interventions
FX006 32 mg
Locations
10
United States
TriWest Research Associates, LLC
El Cajon, California, United States
Biosolutions Research
La Mesa, California, United States
Dream Team Clinical Research (formerly located in Anaheim)
Pomona, California, United States
Dream Team Clinical Research
Pomona, California, United States
Tampa Bay Medical Research, Inc.
Clearwater, Florida, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
April 24, 2018
Primary Completion Date
November 8, 2019
Completion Date
March 9, 2020
Last Updated
January 24, 2024
NCT05986292
NCT06234631
NCT07364578
NCT06488144
NCT07058623
NCT06083480
Lead Sponsor
Pacira Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions